Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sure
Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...
Healthy Returns: Novo Nordisk scoops up Chinese obesity drug to compete with Eli Lilly
Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...
Novo Nordisk Signs $2 Billion Deal for Experimental Obesity Drug
Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese ...
Eli Lilly launches weight-loss drug Mounjaro in India, beats Novo Nordisk to major market
Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...
Why Novo Nordisk Stock Dropped on Monday, but Eli Lilly and Him & Hers Health Popped
First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...
Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer
The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...
Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly
Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...
Novo Nordisk Stock (NVO) Plunges as It Shells Out $2 Billion on Chinese Weight Drug
Novo Nordisk (NVO) just agreed to shell out up to $2 billion for the global rights to a Chinese weight-loss drug—and the market wasn’t ...
Weight loss drug Wegovy to cost around €220 a month as supplies go on market in Ireland
Weight loss “wonder drug” Wegovy will cost Irish users around €220 a month as it is not currently availably under either the ...